New KRAS Inhibitor Daraxonrasib Nearly Doubles Survival in Late-Stage Pancreatic Cancer Trial

For decades, a diagnosis of metastatic pancreatic cancer has come with a grim and rapidly approaching horizon. The disease is notoriously resistant to standard treatments, and the five-year survival rate for patients whose cancer has spread remains stubbornly low at around 3 percent.[1][4]

But the landscape of pancreatic cancer treatment is undergoing a seismic shift. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the presentation of a new targeted therapy called daraxonrasib was met with a 30-second standing ovation from normally reserved oncologists.[1][5]

The enthusiasm is anchored in the final data from the Phase 3 RASolute 302 clinical trial, which demonstrated that daraxonrasib nearly doubles the overall survival time for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC).[1][8]

To understand why daraxonrasib is being hailed as a paradigm-shifting breakthrough, one must look at the genetic engine driving the disease. More than 90 percent of pancreatic cancers are fueled by mutations in the KRAS gene.[1][3]

When mutated, the KRAS protein becomes locked in an active "on" state, continuously signaling cancer cells to multiply and survive. For over forty years, scientists attempted to block this protein, but its smooth, spherical surface lacked the deep pockets necessary for traditional drugs to bind.[2][5]

KRAS earned a reputation as the "undruggable" target of oncology. Daraxonrasib, developed by Revolution Medicines, circumvents this structural challenge by acting as a molecular glue.[5][8]

Instead of trying to bind directly to a hidden pocket, the oral drug binds the active RAS protein to another naturally occurring protein in the cell called cyclophilin A. This bulky complex effectively shuts down the cancer-driving signal.[2][8]

The clinical evidence supporting this mechanism is robust. The RASolute 302 trial enrolled 500 patients across North America, Europe, and Asia who had already received standard chemotherapy but saw their cancer progress.[1][8]

The results, published simultaneously in The New England Journal of Medicine, showed that patients taking a once-daily daraxonrasib pill achieved a median overall survival of 13.2 months, compared to 6.7 months for those receiving standard intravenous chemotherapy.[1][4]

This translates to a 60 percent reduction in the risk of death for this advanced patient population. Furthermore, the drug doubled progression-free survival—the time patients live without their cancer growing—from 3.6 months to 7.2 months.[6][8]

Beyond extending life, the evidence pack highlights a significant improvement in the quality of that time. Standard chemotherapy for pancreatic cancer is notoriously toxic, often causing severe fatigue, neuropathy, and gastrointestinal distress.[4][7]

Daraxonrasib, while not without side effects, presents a more manageable safety profile. Grade 3 or higher treatment-related adverse events occurred in 43.6 percent of patients on the targeted therapy, compared to 57.5 percent on chemotherapy.[6]

The most common side effects associated with daraxonrasib were severe rashes and stomatitis (mouth sores). Crucially, patients on the experimental drug reported significantly delayed deterioration in cancer-related pain and overall global health status.[1][6]

Only 1.2 percent of patients taking daraxonrasib had to discontinue treatment due to side effects, a stark contrast to the 11.2 percent discontinuation rate in the chemotherapy arm.[6]

Regulatory agencies are moving with unprecedented speed to make the drug available. In May 2026, the FDA permitted an expanded access program, allowing physicians to request the drug for eligible patients ahead of formal approval.[6][7]

By July 2026, the FDA formally accepted the New Drug Application (NDA) for daraxonrasib. The drug was selected for the FDA Commissioner’s National Priority Voucher pilot program, which aims to compress the standard review timeline to just one or two months.[6]

The European Medicines Agency (EMA) has also initiated a phased review, granting the drug high-priority status under its Cancer Medicines Pathfinder project.[6]

Despite the overwhelming optimism, transparent uncertainties remain. Like many targeted therapies, patients in the trial eventually developed resistance to daraxonrasib, meaning the cancer found a new way to grow.[2][7]

Additionally, while the drug showed efficacy in the small subset of patients without a known KRAS mutation (RAS wild-type), the sample size was too small to draw definitive conclusions for that specific group.[4][7]

The next frontier of evidence will come from ongoing trials testing daraxonrasib as a first-line treatment—before patients ever receive chemotherapy—and in combination regimens aimed at preventing resistance and further extending survival.[3][7]